Study: Ballesteros-Torres 2025, Nutrition & Metabolism
Impact of ashwagandha (Withania somnifera L.) supplementation on serum lipid concentrations and anthropometric parameters in adults with overweight and obesity: a double-blind, placebo-controlled pilot study
Citation
Ballesteros-Torres JM, Vazquez-Aguilar A, Luzardo-Ocampo I, Escalante-Aburto A et al (2025). Nutrition & Metabolism. PubMed id 41204297.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Ashwagandha: cortisol, mood, skin, hair, heart, kidneys and liver Tier B thin
B 43 adults with overweight or obesity, Mexico (the abstract reports 17 control and 21 intervention) (n=43)
Double-blind, randomised, placebo-controlled pilot, 500 mg a day for 40 days with a monitored diet.
No significant change in weight, BMI or waist circumference. Triglycerides and VLDL cholesterol fell. The authors call for longer studies.
As recorded in this card: Ballesteros-Torres JM, Vazquez-Aguilar A, Luzardo-Ocampo I, Escalante-Aburto A et al (2025), Nutrition & Metabolism, [primary]
Note: Pilot, 40 days. Participant numbers in the abstract do not add up to 43.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.